Open Orphan PLC Investor Event Attendance and Presentation
21 Ottobre 2019 - 8:00AM
RNS Non-Regulatory
TIDMORPH
Open Orphan PLC
21 October 2019
21 October 2019
Open Orphan Plc
("Open Orphan" or the "Company")
Investor Event Attendance and Presentation
Open Orphan presents at The London Investor Show
Open Orphan, a European-focussed, rare and orphan drug
consulting services platform, is pleased to announce that the
Company will be attending and presenting at The London Investor
Show at Novotel London West, London, W6 8DR this Friday 25(th)
October 2019.
Maurice Treacy, Open Orphan's Chief Commercial Officer, will be
in attendance and will be presenting in Conference Room 1 from
11:50am - 12:20pm. Afterwards there will be an opportunity for
existing and potential shareholders to discuss the Company's
business plans moving forward.
The event will run from 09:30am - 5:00pm and all parties
interested in attending can obtain a free ticket by using the
promotional code OPENORPHAN19 when ordering a ticket from the
following link:
http://www.eventdata.co.uk/Forms/Form.aspx?FormRef=LISA9Visitor
.
Enquiries:
Open Orphan Plc Tel: +353 (0)1 6440007
Cathal Friel, Chief Executive Officer
Arden Partners (Nominated Adviser and Joint Broker) Tel: +44
(0)20 7614 5900
John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer
Davy (Euronext Growth Adviser and Joint Broker) Tel: +353 (0)1
679 6363
Anthony Farrell (Corporate Finance)
Camarco (Financial PR) Tel: +44 (0)20 3757 4980
Tom Huddart / Billy Clegg / Daniel Sherwen
Notes to Editors:
Open Orphan plc is a European-focused, rare and orphan drug
consulting services platform. The Company intends to roll up a
number of orphan drug services business. Open Orphan has two data
driven digital platforms, a Genomic Health Data Platform, which is
establishing a rare disease database and a Virtual Rep platform
enabling pharmaceutical companies to engage key opinion leaders and
physicians. The Company is targeting rapid growth in one of the
fastest growing sectors in the global pharmaceutical industry
targeting under-supplied treatment for life threatening or very
serious diseases and rare disorders.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAPGGCAUUPBGMU
(END) Dow Jones Newswires
October 21, 2019 02:00 ET (06:00 GMT)
Grafico Azioni Venn Life Sciences (LSE:VENN)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Venn Life Sciences (LSE:VENN)
Storico
Da Apr 2023 a Apr 2024
